Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Recruiting

Phase 2

Zanubrutinib & VenetoclaxZanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Sponsor:

Weill Medical College of Cornell University

Code:

NCT05650723

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Zanubrutinib Pill

Venetoclax Pill

Obinutuzumab Injection

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-12. This information was provided to ClinicalTrials.gov by Weill Medical College of Cornell University on 2025-03-19.